Tamtam Try Tamtam free
Sinopharm logo

Sinopharm account plan

Pharmaceutical distribution and research

At a glance

Sinopharm Group runs China's largest national drug and medical device distribution network, with FY2025 revenue of RMB575,167.88 million.

Sinopharm Group Co. Ltd. (HKEX 01099) is the core listed subsidiary of the state-owned China National Pharmaceutical Group (CNPGC) and runs the largest national pharmaceutical and medical device distribution network in China. It distributes drugs, medical devices and consumables to hospitals, distributors, retail pharmacies and primary health institutions, runs the Guoda Drugstore and specialty pharmacy chains, and produces pharmaceutical products, chemical reagents and laboratory supplies. FY2025 revenue was RMB575,167.88 million (-1.60%) and profit attributable to owners of the parent RMB7,155.09 million (+1.50%). Headcount was 90,447 at mid-2026, down from 94,910 at end-2025. CNPGC owns 51% of Sinopharm Industrial Investment, which holds 50.36% of the Company, and holds 6.64% directly.

Business units

Strategic priorities

Network consolidation and M&A
Optimise the national distribution and logistics network, carry out mergers and acquisitions around the main business and clean up non-core assets, in 2026, the first year of the 15th Five-Year Plan.
Unified intelligent supply chain platform
Build one platform covering procurement, warehousing, distribution and sales, unify finance, procurement and logistics systems and test artificial intelligence; digital construction covers 15 core departments and 25 key projects.
Innovative-drug commercialisation services
Build a 'second growth curve' in CSO marketing services, specialty pharmacy, SPD and third-party logistics, as innovative drugs are kept out of centralized procurement.
Retail quality over store count
Raise single-store quality and own-brand share at Guoda, convert stores into community health stations, and open hospital-side specialty pharmacies.
Cash flow, lean cost and compliance
Shift from scale to quality and cash flow: the overall expense ratio fell to 4.11% in H1 2026, 'per capita profit' is a core indicator, and a compliance system lists 53 key prevention and control items.

Latest results

In H1 2026 Sinopharm's revenue was RMB282,799.61 million (-1.13%) and net profit RMB5,179.80 million (-2.95%), with profit attributable to owners of the parent of RMB3,403.77 million (-1.79%). Pharmaceutical distribution revenue fell 1.39% and its operating margin slipped to 2.42%, while retail pharmacy grew 8.58% with a 3.00% margin. The overall expense ratio fell 0.27 point to 4.11% and the gearing ratio was 66.29%. Net cash used in operating activities was RMB23,762.76 million, against RMB34,111.09 million a year earlier. No interim dividend was proposed.

Investments and deals

Capex in channels, logistics and IT
Capex was RMB1,917.30 million in FY2025, mainly distribution channels, logistics and IT, and RMB1,578.86 million in H1 2026.
Hospital SPD and centralised distribution projects
72 SPD projects and 68 single-hospital centralised distribution projects added in 2025, and 35 SPD and 28 centralised distribution projects in H1 2026.
Guoda health stations
Sinopharm Accord's Guoda built 30 flagship health stations and upgraded 1,000 community stations, with training for 25,000 staff including 4,000 chronic-disease specialists.
Procurement integration platform
A procurement integration and centralised procurement platform was launched in H1 2026; AI prescription review and member operations are being deployed in retail.

Challenges and risks

Volume-based procurement and price cuts
VBP, price cuts for nationally negotiated drugs and medical insurance cost control pushed distribution revenue down and the gross margin to 7.25% in FY2025 from 7.57%.
Long hospital payment cycles
Trade receivables turnover rose to 130 days in FY2025 from 121, and trade and bills receivables reached RMB205,622 million; management expects payment cycles to keep lengthening.
Compliance pressure
Tighter state regulation of the industry and of medical insurance funds ranks third among the Board's major risks.
Device procurement headwinds
IVD reagent VBP and centralised procurement of large equipment cut device sales; the segment margin was 1.77% in H1 2026.

What leadership says

“industry competition has shifted from scale competition to comprehensive strength competition of efficiency, service, innovation and compliance.”

Jin Bin, Chairman · Sinopharm Group Annual Report 2025, April 2026

“the biggest operation highlight of the year”

Jin Bin, Chairman · On the retail turnaround, Sinopharm Group Annual Report 2025, April 2026

“scale-oriented to quality and cash flow-oriented”

Lian Wanyong, President · MD&A of the Sinopharm Group Annual Report 2025, April 2026

Where a supplier can help

Supply chain digitisation
The unified intelligent supply chain platform and the integration of finance, procurement and logistics systems call for warehouse, traceability and integration software and services.
Receivables and cash collection tools
Lengthening hospital payment cycles and the focus on cash flow make receivables management, credit analytics and collection automation relevant.
Hospital SPD and logistics equipment
The steady stream of new SPD and centralised distribution projects creates demand for hospital logistics automation, cold-chain and inventory systems.
Retail health services and AI
Health stations, AI prescription review and own-brand growth at Guoda open room for retail analytics, testing equipment and staff training providers.
Compliance management
The full-coverage compliance system and its 53 key control items suit compliance monitoring and audit software vendors.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Sinopharm?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Sinopharm

What does Sinopharm Group do?

Sinopharm Group distributes drugs, medical devices and healthcare products across China through the largest national distribution network, runs the Guoda Drugstore and specialty pharmacy chains, and makes pharmaceutical products and lab supplies.

What is Sinopharm Group's revenue?

FY2025 revenue was RMB575,167.88 million (-1.60%), with profit attributable to owners of the parent of RMB7,155.09 million. H1 2026 revenue was RMB282,799.61 million (-1.13%).

How many employees does Sinopharm Group have?

90,447 at mid-2026, down from 94,910 at end-2025 and 108,217 a year earlier.

Who leads Sinopharm Group?

Jin Bin became Chairman on 19 December 2025, replacing Zhao Bingxiang; Lian Wanyong has been President since August 2024.

Who owns Sinopharm Group?

The state-owned CNPGC holds 51% of Sinopharm Industrial Investment, which owns 50.36% of the Company, plus 6.64% directly; Shanghai Fosun Pharmaceutical holds the other 49% of Sinopharm Industrial Investment.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)